Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in patients with cancer

Source
Clinical cancer research - ISSN 1078-0432-29:3 (2023) p. 635-646

Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors

Source
Frontiers in immunology - ISSN 1664-3224-13 (2022) p. 1-10
Author(s)

Ciltacabtagene autoleucel for patients with triple-class exposed multiple myeloma : adjusted comparison of CARTITUDE-1 patient outcomes versus real-world clinical practice

Source
HemaSphere - ISSN 2572-9241-6:12 (2022) p. 1-4
Author(s)
    Michel Delforge, Marie-Christiane Vekemans, Julien Depaus, Nathalie Meuleman, Ann Van de Velde, Isabelle Vande Broek, Sophie Vandervennet, Sandra Van Hoorenbeeck, Evelien Moorkens, Danielle Strens, Joris Diels, Francesca Ghilotti, Benjamin Haefliger, Sander Dalhuisen, William Deraedt, Sébastien Anguille